Compare Becton Dickinson and Co (BDX) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Charles River Laboratories Intl. Inc — how do they compare? Becton Dickinson and Co trades at $180.75 (market cap $49.41B), while Charles River Laboratories Intl. Inc trades at $282 (market cap $13.46B). The key difference: Becton Dickinson and Co is far larger — about 3.7× Charles River Laboratories Intl. Inc's market cap, and Becton Dickinson and Co pays a 2.32% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| BDX | CRL | |
|---|---|---|
Market Cap | $49.41B | $13.46B |
Sector | Health | Health |
52-Week High | $185.39 | $282.00 |
52-Week Low | $138.62 | $145.57 |
Enterprise Value | $65.51B | $16.30B |
Dividend Yield | 2.32% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →
